Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil

Trial Details

NCT ID
NCT05748834
Phase
PHASE2
Sponsor
SCRI Development Innovations, LLC
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Tucatinib
  • Doxil
Locations (sample)
  • Columbia, Maryland, United States|39.24038,-76.83942
  • Bensalem, Pennsylvania, United States|40.10455,-74.95128
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Written informed consent, according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any stu…
  • At least 18 years-of-age at the time of signature of the informed consent form (ICF)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Have a confirmed diagnosis of locally advanced/metastatic HER2+ breast cancer (based on local laboratory testing per American Society of Clinical O…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →